Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

MERCK vs GLENMARK PHARMA - Comparison Results

MERCK    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More


Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More


Current Valuations

P/E (TTM) x 51.1 13.3 383.5% View Chart
P/BV x 8.9 2.4 374.1% View Chart
Dividend Yield % 0.4 0.4 86.4%  


5-Yr Chart
Click to enlarge
High Rs1,358930 146.0%   
Low Rs933517 180.3%   
Sales per share (Unadj.) Rs665.0322.6 206.1%  
Earnings per share (Unadj.) Rs56.628.5 198.6%  
Cash flow per share (Unadj.) Rs72.539.2 184.9%  
Dividends per share (Unadj.) Rs15.002.00 750.0%  
Dividend yield (eoy) %1.30.3 473.9%  
Book value per share (Unadj.) Rs441.7183.0 241.4%  
Shares outstanding (eoy) m16.60282.17 5.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.2 76.8%   
Avg P/E ratio x20.225.4 79.7%  
P/CF ratio (eoy) x15.818.5 85.6%  
Price / Book Value ratio x2.64.0 65.6%  
Dividend payout %26.57.0 377.7%   
Avg Mkt Cap Rs m19,011204,206 9.3%   
No. of employees `0001.513.7 11.3%   
Total wages/salary Rs m1,69618,718 9.1%   
Avg. sales/employee Rs Th7,150.06,636.8 107.7%   
Avg. wages/employee Rs Th1,098.71,364.7 80.5%   
Avg. net profit/employee Rs Th608.2586.1 103.8%   
Net Sales Rs m11,04091,031 12.1%  
Other income Rs m240914 26.2%   
Total revenues Rs m11,27991,945 12.3%   
Gross profit Rs m1,37616,154 8.5%  
Depreciation Rs m2643,019 8.7%   
Interest Rs m02,856 0.0%   
Profit before tax Rs m1,35211,193 12.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m5833,155 18.5%   
Profit after tax Rs m9398,039 11.7%  
Gross profit margin %12.517.7 70.2%  
Effective tax rate %43.128.2 153.0%   
Net profit margin %8.58.8 96.3%  
Current assets Rs m7,52369,887 10.8%   
Current liabilities Rs m2,25332,879 6.9%   
Net working cap to sales %47.740.7 117.4%  
Current ratio x3.32.1 157.1%  
Inventory Days Days5281 64.1%  
Debtors Days Days4193 43.4%  
Net fixed assets Rs m1,24028,892 4.3%   
Share capital Rs m166282 58.8%   
"Free" reserves Rs m7,16751,353 14.0%   
Net worth Rs m7,33351,635 14.2%   
Long term debt Rs m041,418 0.0%   
Total assets Rs m9,912125,954 7.9%  
Interest coverage xNM4.9-  
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x1.10.7 154.1%   
Return on assets %9.58.6 109.5%  
Return on equity %12.815.6 82.3%  
Return on capital %20.815.1 137.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,01536,317 2.8%   
Fx outflow Rs m3,0439,720 31.3%   
Net fx Rs m-2,02826,598 -7.6%   
From Operations Rs m53716,481 3.3%  
From Investments Rs m-476-10,133 4.7%  
From Financial Activity Rs m-220-4,685 4.7%  
Net Cashflow Rs m-1601,770 -9.0%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 6.9 263.8%  
FIIs % 1.0 34.4 2.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.5 277.1%  
Shareholders   28,591 56,727 50.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster


Compare MERCK With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Today's Market

Sensex Ends 157 Points Higher; Metal and Power Stocks Rally(Closing)

Indian share markets traded on a positive note most of the day and ended higher. Gains were largely seen in the metal sector, power sector and realty sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Jun 26, 2019 03:36 PM